Nasdaq
$0.5335▲ 0.00%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $52.9MShares out 99.2M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
10- 10.6After-hours26.10.07 05:078-KKey event#●●●#●●●#●●●
Caribou Biosciences, Inc.Bullish
Caribou Biosciences has decided to discontinue the clinical development of its core programs, vispa-cel and CB-011, due to a challenging financing environment and will explore strategic alternatives. The company is implementing a significant workforce reduction, expected to be largely completed in the fourth quarter of 2026. As of June 30, 2026, the company held $113.8 million in cash and cash equivalents, with anticipated restructuring costs ranging from $15 million to $19 million.…more
$0.5335+0.00%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.6After-hours26.08.14 05:11filed10-QEarnings
Caribou Biosciences, Inc.
Caribou Biosciences has filed its quarterly report (Form 10-Q) for the period ended June 30, 2026. The filing includes certifications from the company's executive officers regarding the accuracy of its financial statements and operational results.…more
$0.5335+0.00%vs prev closeView filingShare - 10.6After-hours26.08.14 05:07filed8-KKey event
Caribou Biosciences, Inc.
Caribou Biosciences reported a net loss of $24.3 million and revenue of $1.5 million for the second quarter of 2026. The company holds $113.8 million in cash and cash equivalents, which is expected to fund its current operating plan through the end of 2027. Clinical data for its lead programs, vispa-cel and CB-011, continue to demonstrate safety and efficacy profiles comparable to existing approved therapies.…more
$0.5335+0.00%vs prev closeView filingShare
9 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.7Overnight26.10.07 15:27#●●●#●●●#●●●
Stocks to Watch: Levi Strauss, Constellation Brands, and More
Constellation Brands shares fell despite beating earnings estimates and raising guidance, while Caribou Biosciences plummeted after announcing the discontinuation of its therapy programs. Investors are now awaiting quarterly results from Levi Strauss and Applied Digital after the market close.…more
$0.5335+0.00%vs prev closeShareBenzinga
- 10.7Overnight26.10.07 14:34
●●●●●●●● ●●●●● ●●●●●●
Caribou Biosciences announced it will discontinue its two main cell therapy programs and explore strategic alternatives, including a potential sale. The company also plans significant workforce reductions due to challenges in securing capital.…more
$0.5335+0.00%vs prev closeShareBenzinga - 10.6After-hours26.10.07 05:20
●●●●●●●● ●●●●● ●●●●●●
The trading halt for the specified security has been lifted and quotation has resumed. Investors should review the latest news and filings to inform their investment decisions.…more
$0.5335+0.00%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report